Insulet (PODD)
(Delayed Data from NSDQ)
$200.45 USD
-1.39 (-0.69%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $200.50 +0.05 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Brokerage Reports
Insulet Corporation [PODD]
Reports for Purchase
Showing records 121 - 140 ( 342 total )
Company: Insulet Corporation
Industry: Medical - Products
EU Upside Bodes Well Ahead of the Sales Force Transition
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Neulasta Onpro Tracker (September): Demand Beginning to Slow
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Medical Devices - 3Q17 Earnings Preview: Anti-climatic due to Seasonally Soft Qtr and Hurricanes
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Neulasta Onpro Tracker (August): Typical Share Decline After a Strong July
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Neulasta Onpro Tracker (July): Share Up; Quirk in Rx Data Limits Interpretation
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Medical Devices - Healthcare Conference
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Solid Quarter and Greater Confidence In PODD''s New European Sales Strategy
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Neulasta Onpro RX Tracker (June): Adoption Rises for the Month and Quarter
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
2Q17 Earnings Preview: Positive Underlying Dynamics
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Monthly Neulasta Onpro RX Tracker (May): Share Continues to Steadily Increase
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Diabetes Technology Insights from the ADA
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Initial End-User Feedback on 670G System Somewhat Mixed, But A Step In The Right Direction
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Monthly Neulasta Onpro Prescription Tracker (April): Penetration Inches Higher to 52%
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Insulet''s 1Q Results Stands out Among its Diabetes Peers; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Discontinuation of Research Coverage
Provider: Feltl & Company